AMERGE
LOE ApproachingNDAORALTABLET
Approved
Feb 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMERGE (naratriptan) is an oral tablet small-molecule triptan approved in 1998 for acute migraine treatment. It works by binding to serotonin 5-HT1B/1D receptors to cause cranial vasoconstriction and inhibit neuropeptide release. The drug is indicated for rapid symptomatic relief in patients experiencing migraine attacks.
LOE Approaching
As a mature triptan entering LOE, the AMERGE team likely operates with stable but declining resources, focusing on retention and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Special Drug Use Investigation for AMERGE® Tablet (Long-term)
Started May 2009
300 enrolled
Migraine Disorders
Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet
Started Apr 2009
500 enrolled
Migraine Disorders
Career Relevance
Working on AMERGE offers limited growth trajectory but provides solid experience in managing a stable, mature brand through LOE transition. Roles emphasize defensive market strategies, payer negotiations, and cost optimization rather than launch or expansion.
Brand Manager
Worked on AMERGE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.